299. Cystic fibrosis Clinical trials / Disease details


Clinical trials : 1,696 Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170

  
6 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02054156
(ClinicalTrials.gov)
June 20141/2/2014OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic FibrosisOPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized TrialCystic FibrosisDrug: azithromycin;Drug: placebo;Drug: Tobramycin solution for inhalationBonnie RamseyNational Heart, Lung, and Blood Institute (NHLBI)Completed6 Months18 YearsAll221Phase 3United States
2NCT01460836
(ClinicalTrials.gov)
April 201025/10/2011Indirect Comparison of Tobramycin Solution for Inhalation Versus Aztreonam Lysine for Inhalation in the Treatment of Cystic FibrosisIndirect Comparison of Tobramycin Solution for Inhalation Versus Aztreonam Lysine for Inhalation in the Treatment of Cystic FibrosisCystic FibrosisDrug: Tobramycin solution for inhalation;Drug: Aztreonam lysine for inhalationNovartis PharmaceuticalsNULLCompleted6 YearsN/ABothN/ANULL
3NCT00547053
(ClinicalTrials.gov)
December 200617/10/2007Amiloride Solution and Tobramycin Solution for Inhalation for the Eradication of Burkholderia Dolosa in Patients With Cystic FibrosisA Six Month Open Label Study of Amiloride Solution for Inhalation and Tobramycin Solution for Inhalation for the Eradication of Burkholderia Dolosa in Patients With Cystic FibrosisCystic FibrosisDrug: Amiloride Solution for InhalationChildren's Hospital BostonCystic Fibrosis Foundation TherapeuticsCompleted6 YearsN/ABoth25Phase 1United States
4NCT00388505
(ClinicalTrials.gov)
February 200616/10/2006Safety of Tobramycin Inhalation Powder (TIP) vs Tobramycin Solution for Inhalation in Patients With Cystic FibrosisA Randomized, Open-label Multicentre Phase 3 Trial to Assess the Safety of Tobramycin Inhalation Powder Compared to Tobramycin Solution for Inhalation in Cystic Fibrosis SubjectsCystic FibrosisDrug: Tobramycin Inhalation Powder;Drug: Tobramycin Solution for InhalationNovartis PharmaceuticalsNULLCompleted6 YearsN/AAll517Phase 3United States;Australia;Canada;Chile;Colombia;France;Germany;Hungary;Israel;Italy;Mexico;Netherlands;Spain;United Kingdom
5NCT00097773
(ClinicalTrials.gov)
September 200430/11/2004Comparison of Two Treatment Regimens to Reduce PA Infection in Children With Cystic FibrosisEffectiveness and Safety of Intermittent Antimicrobial Therapy for the Treatment of New Onset Pseudomonas Aeruginosa Airway Infection in Young Patients With Cystic FibrosisCystic Fibrosis;Pulmonary Disease, Chronic ObstructiveDrug: Tobramycin solution for inhalation (TOBI);Drug: Oral placebo;Drug: Oral ciprofloxacinSeattle Children's HospitalNational Heart, Lung, and Blood Institute (NHLBI);Cystic Fibrosis Foundation Therapeutics;CF Therapeutics Development Network Coordinating CenterCompleted1 Year12 YearsAll304Phase 2United States
6NCT00391976
(ClinicalTrials.gov)
November 200319/10/2006Efficacy and Safety of 28 or 56 Day Treatment for Pseudomonas Aeruginosa in Children With Cystic FibrosisThe Microbiologic Efficacy and Safety of Two Treatment Regimens of Inhaled Tobramycin Nebuliser Solution (TNS) for the Treatment of Early Onset Pseudomonas Aeruginosa Lower Respiratory Tract Infection in Subjects With Cystic FibrosisCystic FibrosisDrug: Tobramycin solution for inhalation 300 mgNovartisNULLCompleted6 MonthsN/AAll123Phase 3NULL